
PAROEX- chlorhexidine gluconate rinse Sunstar Americas, Inc.

Chlorhexidine Gluconate Oral Rinse USP, 0.12%

Description:

Paroex® is an oral rinse containing 0.12% chlorhexidine gluconate (1,1'-hexamethylene bis [5-(p-chlorophenyl) biguanide] di-D-gluconate) in a base containing deionized water, propylene glycol, glycerin, polyoxyl 40 hydrogenated castor oil, mint flavor, potassium acesulfame, FD&C Red #40 and D&C Red #33. Paroex® is a near-neutral solution (pH range 5-7). Chlorhexidine gluconate is a salt of chlorhexidine and gluconic acid. Its chemical structure is:



Clinical Pharmacology:

Paroex® provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general reduction of counts of certain assayed bacteria, both aerobic and anaerobic, ranging from 54-97% through six months' use.

Use of chlorhexidine gluconate oral rinse in a six-month clinical study did not result in any significant changes in bacterial resistance, overgrowth of potentially opportunistic organisms or other adverse changes in the oral microbial ecosystem. Three months after chlorhexidine oral rinse use was discontinued, the number of bacteria in plaque had returned to baseline levels and resistance of plaque bacteria to chlorhexidine gluconate was equal to that at baseline.

Pharmacokinetics:

Pharmacokinetics studies with 0.12% chlorhexidine gluconate oral rinse indicate approximately 30% of the active ingredient is retained in the oral cavity following rinsing. The retained drug is slowly released into the oral fluids. Studies conducted on human subjects and animals demonstrate chlorhexidine gluconate is poorly absorbed from the gastrointestinal tract. The mean plasma level of chlorhexidine gluconate reached a peak of 0.206 µg/g in humans 30 minutes after they ingested a 300 mg dose of the drug. Detectable levels of chlorhexidine gluconate were not present in the plasma of these subjects 12 hours after the compound was administered. Excretion of chlorhexidine gluconate occurred primarily through the feces (~90%). Less than 1% of the chlorhexidine gluconate ingested by these subjects was excreted in the urine.

Indications and Usage:

Paroex® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Paroex® has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, SEE PRECAUTIONS.

Contraindications:

Paroex[®] should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

Warnings:

The effect of Paroex® on peridontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chlorhexidine gluconate oral rinse users compared with control users. It is not known if chlorhexidine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. SEE CONTRAINDICATIONS.

PRECAUTIONS: GENERAL

- 1. For patients having coexisiting gingivitis and periodontitis, the presence or absence of gingival inflammation following treatment with Paroex® should not be used as a major indicator of underlying periodontitis.
- 2. Paroex® can cause staining of oral surfaces, such as tooth surfaces, restorations, and the dorsum of the tongue. Not all patients will experience a visually significant increase in toothstaining. In clinical testing, 56% of chlorhexidine gluconate oral rinse users exhibited a measurable increase in facial anterior stain, compared to 35% of control users after six months; 15% of chlorhexidine gluconate oral rinse users developed what was judged to be heavy stain, compared to 1% of the control users after six months. Stain will be more pronounced in patients who have heavier accumulations of unremoved plaque.

Stain resulting from use of Paroex® does not adversely affect health of the gingivae or other oral tissues. Stain can be removed from most tooth surfaces by conventional professional prophylactic techniques. Additional time may be required to complete the prophylaxis. Discretion should be used when prescribing to patients with anterior facial restorations with rough surfaces or margins. If natural stain cannot be removed from these surfaces by a dental prophylaxis, patients should be excluded from Paroex® treatment if permanent discoloration is unacceptable. Stain in these areas may be difficult to remove by dental prophylaxis and on rare occasions may necessitate replacement of these restorations. 3. Some patients may experience an alteration in taste perception while undergoing treatment with Paroex® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%). Rare instances of permanent taste alteration following chlorhexidine gluconate oral rinse use have been reported via post-marketing product surveillance.

Pregnancy:

Teratogenic Effects *Pregnancy Category B*. Reproduction studies have been performed in rats and rabbits at chlorhexidine gluconate doses up to 300 mg/kg/day and 40 mg/kg/day, respectively, and have not revealed evidence of harm to fetus. However, adequate and well-controlled studies in pregnant women have not been done. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Paroex® oral rinse is administered to nursing women.

In parturition and lactation studies with rats, no evidence of impaired parturition or of toxic effects to

suckling pups was observed when chlorhexidine gluconate was administered to dams at doses that were over 100 times greater than that which would results from a person's ingesting 30 mL (2 doses) of chlorhexidine gluconate per day.

Pediatric Use:

Clinical effectiveness and safety of Paroex[®] have not been established in children under the age of 18.

Carcinogenesis, Mutagenesis, and Impairment of Fertility:

In a drinking water study in rats, carcinogenic effects were not observed at doses up to 38 mg/kg/day. Mutagenic effects were not observed in two mammalian in vivo mutagensis studies with chlorhexidine gluconate. The highest doses of chlorhexidine used in a mouse dominant-lethal assay and a hamster cytogenetics test were 1000 mg/kg/day and 250 mg/kg/day, respectively. No evidence of impaired fertility was observed in rats at doses up to 100 mg/kg/day.

Adverse Reactions:

The most common side effects associated with chlorhexidine gluconate oral rinse are: 1) an increase in staining of the teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; see WARNINGS and PRECAUTIONS.

Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse. The following oral mucosal side effects were reported during placebo-controlled adult clinical trails: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1.0%. Among post marketing reports, the most frequently reported oral mucosal symptoms associated with chlorhexidine gluconate oral rinse are stomatitis, gingivits, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia. Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using chlorhexidine gluconate oral rinse. There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using chlorhexidine gluconate oral rinse.

Overdosage:

Ingestion of 1 or 2 ounces of Paroex[®] (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) by a small child (~10 kg body weight) might result in gastric distress, including nausea. Medical attention should be sought if more than 4 ounces of Paroex[®] is ingested by a small child.

Dosage and Administration:

Paroex® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) therapy should be initiated directly following a dental prophylaxis. Patients using Paroex® should be reevaluated and given a thorough prophylaxis at intervals no longer than six months. Recommended use is twice daily, oral rinsing 30 seconds, morning and evening after toothbrushing. Usual dosage is 15 mL (1/2 FL OZ marked in cup) of undiluted Paroex®. Patients should be instructed not to rinse with water, or other mouthwashes, brush teeth, or eat immediately after using Paroex®. Paroex® is not intended for ingestion and should be expectorated after rinsing.

How Supplied:

Paroex® is supplied as a pink liquid in the following sizes:

4 fl oz (118 ml) (NDC 52376-021-04) amber plastic bottles with child-resistant cap.

16 fl oz (473 mL) (NDC 52376-021-02) amber plastic bottles with child-resistant cap, individually shirnk wrapped with a dosage cup.

STORE at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F)

[See USP controlled room temperature].

Rx Only Keep Out Of Reach Of Children

Manufactured for: Sunstar Americas, Inc., 301 E. Central Rd. Schaumburg, IL 60195

Revised: September 2017

Directions for Use:

To open, press down while turning the cap. To seal, turn until cap clicks and is tight.

Fill dosage cup to the fill line (15 mL). Swish in your mouth undiluted for 30 seconds, then **spit out**. Use after breakfast and before bedtime. Or, use as prescribed by your dentist.

Note: To minimize medicinal taste, do not rinse with water immediately after use. Rx Only

Keep Out Of Reach Of Children

Ingredients:

0.12% chlorhexidine gluconate in a base containing deionized water, propylene glycol, glycerin, polyoxyl 40 hydrogenated castor oil, mint flavor, potassium acesulfame, FD&C Red #40 and D&C Red #33.

WHAT TO EXPECT WHEN USING Paroex® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%):

Your dentist has prescribed Paroex[®] to treat your gingivitis - to help reduce the redness and swelling of your gums, and also to help you control any gum bleeding.

Use Paroex® regularly, as directed by your dentist, in addition to daily brushing and flossing. Spit out after use. Paroex® should not be swallowed.

If you develop allergic symptoms such as skin rash, itch, generalized swelling, breathing difficulties, light headedness, rapid heart rate, upset stomach or diarrhea, seek medical attention immediately. Paroex® should not be used by persons who have a sensitivity to it or its components.

Paroex® may cause some tooth discoloration, or increases in tartar (calculus) formation, particularly in areas where stain and tartar usually form. It is important to see your dentist for removal of any stain and tartar at least every six months, or more frequently if your dentist advises.

- Both stain and tartar can be removed by your dentist or hygienist. Chlorhexidine gluconate oral rinse may cause permanent discoloration of some front-tooth fillings.
- To minimize discoloration, you should brush and floss daily, emphasizing areas which begin to discolor.
- Paroex® may taste bitter to some patients and can affect how foods and beverages taste. This will become less noticeable in most cases with continued use of Paroex®.
- To avoid taste interference, rinse with Paroex® *after* meals. Do not rinse with water or other mouthwashes immediately after rinsing with Paroex®.

If you have questions or comments about Paroex[®], contact your dentist, pharmacist or Sunstar Americas, Inc. at 1-800-528-8537. Call your health care provider for medical advice about side effects. You may reprot side effects to FDA at 1-800-FDA-1088.

STORE at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled room temperature].

Manufactured for: Sunstar Americas, Inc., 301 E. Central Rd. Schaumburg, IL 60195

Principal Display Panel

NDC 052376-021-02 1789P

SUNSTAR

GUM®

Paroex®

CHLORHEXIDINE GLUCONATE ORAL RINSE USP, 0.12%

Alcohol Free

Rx Only


KEEP OUT OF REACH OF CHILDREN

PLACE PHARMACY LABEL HERE

Dispense in bottle as provided or amber glass

1 Pint (473 mL)

© Sunstar Americas, Inc. D0C04649 P17265



ADVERSE REACTIONS (continued):

Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorihexidire gluconate rinse. The following oral mucosal side effects were reported curing placebo-controlled adult clinical trials: aphthous ulcer, grossyle dvisus ignigitis, trauma, ulceration, erythema, desquamation, casted tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1.0%. Among post markeling reports, the most frequently reported oral muccasal symptoms associated with clubtraxicine gluconate oral rinse are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia. Minor irritation and superficial desquamation of the oral mucosa have been noted in patterts using chlorhexidine gluconate oral rinse. There have been cases of parctid gland swelling and inflammation of the salivary glands (sialadentitis) reported in patients using chlorhexidine gluconate oral rinse.

OVERDOSAGE: Ingestion of 1 or 2 ounces of Parcex® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) by a small child (--10 kg bydy weight) might result is gestric distance. Industing generation

INDICATIONS AND USAGE: Paroex[®] (Chlorhexidine Giuconate Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Paroex[®] has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS.

CONTRAINDICATIONS: Paroex® should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

WARNINGS: The effect of Paroex® on periodonitiis has not been determined. An increase in supragingival calculus was noted in clinical testing in chiorhexidine gluconate oral rinse users compared with control users. It is not known if chiorhexidine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported divide negativation use with detal products coefficience objecteding. o.12 m by a smar child (~10 kg body weight) hight result in gastro distress, including nausea. Medical attention should be sought if more than 4 cunces of Paroex[®] is ingested by a small child. DOSAGE AND ADMINISTRATION: Parcex[®] (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) therapy should be initiated directly following a dental prophylaxis. Patierts using Parcex[®] should here provide so that a thorough prophylaxis at intervals no longer than six months. Recommended use is twice daily, oral insing for 30 seconds, morning and evening after toothbrushing. Usual dosage is 15 mL (7 ± 10 . Zm arked in sup) of undiluted Panex⁴. Patients should be instructed not to rinse with water, or other mouthwashes, brush teeth, or eat immediately after using Paroex®. Paroex® is not intended for ingestion and should be expectorated after rinsing. HOW SUPPLIED: Paroex® is supplied as a pink liquid in the following sizes: 4 fl oz (118 ml) (NDC 52376-021-04) amber plastic bottles with child-resistant cap. 16 fl oz (473 ml) (NDC 52376-021-02) amber plastic bottles with child-resistant cap, individually shrink wrapped with a dosage cup. STORE at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled room temperature] Rx Only Keep Out Of Reach Of Children Manufactured for: Sunstar Americas, Inc., 301 E. Central Rd, Schaumburg, IL 60195 Revised: September 2017 RD ON RD ON More and of Children
 Providents: 0.12% circinizations guodinate in base containing denotized vaser, propilere plycol, discriptions, 0.10% violations and solutions and solutions and solutions
 More Transferrences. Only minimum sciences and solutions
 More Transferrences
 More Transferrence
 More Trans wn while turning cap. To seal, turn until cap elicise and is tight. Te fill observable the fill mile (5 mL) swish in your mouth unditural for 30 aut. Use after breaktast and before beforme. On, uses as prescribed by your dentise modelinal teach, do not thraw white immediately after use. containing deionized water, propylene glycol, or, potassium acesultame, FD&C Red #40 and stain 301 E. Central Rd, Schaumburg, L 60195 temperature]. Americas, Inc., 3 Sunstar down Use: for: H press s for then : Direction seconds, Note: To I Rx Only Keep Ou Ingredia glycerin D&C Rei WHAT 7 Your der

PEEL TO OPEN + PRESS TO CLOSE

NDC 52376-021-04

1788P

SUNSTAR

GUM®

PAROEX®

Chlorhexidine Gluconate

Oral Rinse USP, 0.12%

ALCOHOL FREE

Rx Only

KEEP OUT OF REACH OF CHILDREN

4 fl oz (118mL)

equal

to that at baseline

levels and resistance of plaque discontinued, the number of ba

© Sunstar Americas, Inc.

LBL02303 R04 P17266

Tregnancy texted by the children of the second could be a second to the second Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Paroex® oral rinse is administr all'e excitette in numeri team, ceated a section of ended to a section of team of the section of of chlorhexidine gluconate per day. Pediatric Use: Clinical effectiveness and safety of Paroex® have not been established in children under the age of 18.

Carcinogenesis, Mutagenesis, Impairment of Fertility: In a drinking water study in rats, carcinogenic effects were not observed at doses up to 38 mg/kg/day. Mutagenic effects were not observed in two mammalian in vivo mutagenesis studies with chlorhexidine gluconate. The highest doses of chlorhexidine used in a mouse dominant-lethal assay and a hamster cytogenetics test were 1000 mg/kg/day and 250 mg/kg/day, respectively. No evidence of impaired fertility was observed in rats at doses up to 100 mg/kg/day.

ADVERSE REACTIONS: The most common side effects associated with chlorhexidine gluconate oral rinse are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; see WARNINGS and PRECAUTIONS.

 For patients having coexisting gingivitis and periodontitis, the presence or absence of gingival inflammation following treatment with Paroex® should not be used as a major indicator of underlying periodontitis. 2. Paroex[®] can cause staining of oral surfaces, such as tooth surfaces, restorations, and the dorsun In clinical testing, 56% of chlorhexidine gluconate oral visually significant increase into other toothstaining. In clinical testing, 56% of chlorhexidine gluconate oral rinse users exhibited a measurable increas in facial anterior stain, compared to 35% of control users after six months; 15% of chlorhexidine

se willi dentai products conta

See CONTRAINDICATIONS.

PRECAUTIONS:

gluconate oral rinse users developed what was judged to be heavy stain, compared to 1% of control users after six months. Stain will be more pronounced in patients who have heavier accumulations of unremoved plaque. Stain resulting from use of Paroex* does not adversely affect accumulations or unremoved paque. Scalar resource prove the or anotex does not adversely at health of the gina/wae or other oral tissues. Stain can be removed from most tooth surfaces by conventional professional prophylactic techniques. Additional time may be required to complet the prophylaxis. Discretion should be used when prescribing to patients with anterior facial restorations with rough surfaces or margins. If natural stain cannot be removed from these surfaces by a dental prophylaxis, patients should be excluded from Parcex[®] treatment if permanent discoloration is unacceptable. Stain in these areas may be difficult to remove


product surveillance. ncy: Teratogenic Effects, Pregnancy Category B. Reproduction studies have been performed in Pregn

by dental prophylaxis and on rare occasions may necessitate replacement of these restorations.

3 Some patients may experience an alteration in faste perception while undergoing treatment with Paroex® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%). Rare instances of permanent taste alteration following chlorhexidine gluconate oral rinse use have been reported via post-marketing methods.







The highest doses of chlorhexidine used in a mouse dominant-lethal assay and a hamster cytogenetics test were 1000 mg/kg/day and 250 mg/kg/day, respectively. No evidence of impaired fertility was observed is at doses up to 100 mg/kg/day.

ADVERSE REACTIONS: The most common side effects associated with Adverse incarinos: The hist common side effects associated with chlorhexidine gluconate oral firse are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; see WARNINGS and PRECAUTIONS. S) an attendation in tasks perception, see warmings and PrecAdd Intes. Oral inflation and local altery-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse. The following oral mucosal side effects were reported during placebo-controlled adult clinical trialis: anythous ulcer, grossy obvious glingivitis, trauma, ulceration, erythema, desquamation, coated tongue, gingivits, trauma, ulceration, erythema, desquamation, coated tongue, koratinization, geographic tongue, muccecle, and short frenum. Each occurred at a frequency of less than 1.0%. Among post markeling reports, the most frequently reported oral mucceasi symptomes associated with chlorhexidine gluconate oral rines are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal dema, and paresthesia. Minor irritation and superficial desquamation of the oral mucces have been noted in patients using chlorhexidine gluconate oral rines. There have been cases of partid gland swelling and inflammation of the salivary glands (sialadentits) reported in patients using chlorhexidine gluconate oral rines. gluconate oral rinse.

OVERDOSAGE: Ingestion of 1 or 2 ounces of Paroex[®] (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) by a small child (~10 kg body weight) might result in gastric distress, including nausea. Medical attention should be sought if more than 4 ounces of Paroex[®] is ingested by a small child.

DOSAGE AND ADMINISTRATION: Parcex[®] (Chiorhexidine Gluconate Oral Rinse USP, 0.12%) therapy should be initiated directly following a dental prophylaxis. Patients using Parcex[®] should be reevaluated and given a thorough prophylaxis at intervals no longer than six months. Recommended use is twice daily, oral rinsing for 30 seconds, morning and evening after toothbrushing. Usual dosage is 15 m. d our didluted Parcex[®]. Patients should be instructed not to rinse with water, or other mouthwashes, brush teeth, or eat immediately after using Parcex[®]. Parcex[®] is not intended for ingestion and should be expectorated after rinein. rinsing.

HOW SUPPLIED: Parcex® is supplied as a pink liquid in the following sizes: 4 fl oz (118 mi) (NDC 52376-021-04) amber plastic bottles with child-resistant cap. 16 fl oz (473 mi) (NDC 52376-021-02) amber plastic bottles with

child-resistant cap, individually shrink wrapped with a dosage cup.

STORE at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled room temperature].

Rx Only Keep Out Of Reach Of Children

Manufactured for: Sunstar Americas, Inc., 301 E. Central Rd, Schaumburg, IL 60195 Revised: September 2017

PHARMACOUNETICS: Pharmacokinetics studies with 0.12% chlorhoxidim oluconate oni fines indicate approximately 30% of the active ingredient is retained in the oral cavity following rinsing. This retained drug is slowly released in the oral fluids. Studies conducted on human subjects and animals demonstrate chlorhaxiding gluconate is poorly absorbed from the pastrointestimal tract. The mean plasma level of chlorhexidine gluconate reached a peak of 0.206 µg/g in humans 30 minutes after the yingestea 300 mg does of the drug. Detectable levels of chlorhexidine gluconate and present in the plasma of these subjects 12 human staffer the compand was administered. Excretion of chlorhexidine gluconate occurred plimarity through the foces (~90%). Less than 1% of the chlorhexiding gluconate ingested by these subjects was excreted in the urino. INDICATIONS AND USAGE: Parcex[®] (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivan, including gingival bleeding upon probing, Parcex[®] has not been tested among patients with acute necrotizing ulcerative gingivitis, AU(G). For patients having coexisting gingivitis and periodontitis, see **PRECAUTIONS**.

PHARMACOKINETICS: Pharmacokinetics studies with 0.12% chlorhexidine

CONTRAINDICATIONS: Paroex® should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients

Marchines: The effect of Parcex[®] on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chilorbex/dine gluconate oral rinse users compared with control users. It is not known if chilorbex/dine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophysics at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chilorhexidine. See **CONTRAINDICATIONS**.

PRECAUTIONS:

General 1. For patients having coexisting gingivitis and periodontitis, the presence or absence of gingival inflammation following treatment with Paroex® should not be used as a major indicator of underlying

Or patients neurol colosanty anginers table periodicity of the presence of advects and periodicity of the presence of advects and periodicity of the paranet strength of the used as a major indicator of underlying restances of advects and the document of the tongue. Not all patients will experience a visually adjustication of the tongue. Not all patients will experience a visually adjustication of the tongue. Not all patients will experience a visually adjustication of the tongue. Not all patients will experience a visually adjustication increase in toothstaining. In chincal testing, 55% of control users after six months, 15% of Cohenexidine gluconate card intere users developed what was judget to be heavy state, compared to 1% of control users after six months. Six of Cohenexidine gluconate card intere users developed what was judget to be heavy state, compared to 1% of control users after six months. Six of Cohenexidine gluconate card intere users developed what was judget to be heavy state, compared to 1% of control users after six months. Six of cohenexidine gluconate card interes by commentional professional prohybach: Electricates by commentional professional prohybach: Electricates and the required to complete the prophysics. Discretion handuate bus encouved from Parenet discretations is unacceptable. Sixin for the searce does not not advece by a denial prohybach: Electricate and the required the completions to the searce of the reacting to patients with anterior feelal restorations is unacceptable. Sixin in these areas any be different to remove the develation provement and the searce of commendation of the searce.
Some cost patients and the reace of commendate. Sixin framewore the searce of the reaction of the searce of the reaction of the searce.
Some cost patients after the reace of commendate. Sixin framewore the searce of the reaction of the searce of the reaction of the searce of the reaction of the reaction of the searce of the reaction of the searce of the r

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Paroex® oral rinse is administered to nursing women.

women. In parturition and lacitation studies with rats, no evidence of impaired parturition or of toxic effects to suckling pups was observed when chiorhouting gluconatis was administered to dams at doese that were over 100 times greater than that which would result from a person's ingesting 30 mil (2 doese) of chiorhoxidine gluconate per day. **Pediatric Use:** Chincial effectiveness and safety of Pareve[®] have not been established in children under the age of 18. **Carcinogeness, Mutagenessis, Impairment of Fertility:** In a drinking water study in rats, carcinogenic effects were not observed at doese up to 38 mpKndret were not observed in town

to 38 mg/kg/day. Mutagenic effects were not observed in two mammalian in vivo mutagenesis studies with chlorhexidine gluconate.

Mutual and the second s cap clicks and is tight. Inly nyour mouth unduluted for 30 seconds, e as prescribed by your dentist. er immediately after use. Cap press down while turning cap. To seal, turn until ca to for Use: Swish one tablespoon of oral rinse (15 m) i t out. Use after breaktast and before bedfirme. Or, use as minimize medicinal taste, do not rinse with water in

PEEL TO OPEN . PRESS TO CLOSE

	onate rin	50					
Product Inform	ation						
Product T ype		HUMAN PRESCRIPTION	HUMAN PRESCRIPTION DRUG		ode (Source)	NDC:52376-021	
Route of Administration		ORAL	ORAL				
Active Ingredie	nt/Activ	ve Moiety					
		Ingredient Name	edient Name		Basis of Strength		Strength
CHLORHEXIDINE G UNII:R4KO0DY52L)	LUCONA	ATE (UNII: MOR84MUD8E) (CHLOF	I: MOR84MUD8E) (CHLORHEXIDINE -		CHLORHEXIDINE GLUCONATE		1.2 mg in 1 mL
Product Charac	teristic	S					
Color				Score			
Shape				Size			
		MINT (Mint Flavor)	nt Flavor) Imprint Code		it Code		
Contains							
Packaging							
# Item Code		Package Description	Package Description		_		ting End Date
1 NDC:52376-021- 02	473 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combin Product			04/	04/15/2006		
2 NDC:52376-021- 04	118 mL in Product	1 BOTTLE, PLASTIC; Type 0: Not	LE, PLASTIC; Type 0: Not a Combination		10/31/2014		
Marketing In	forma	ition					
Marketing Category A		plication Number or Monogra	h Citation	Marke	ting Start Date	Marketing End Date	

Labeler - Sunstar Americas, Inc. (025066358)

Revised: 5/2018

Sunstar Americas, Inc.